Regulatory

HHS Interim Policy on Six Peptides: What the Document Says

Published October 28, 2026 · 7 min read

On Wednesday, October 28, 2026, HHS announced that it will temporarily stop enforcing the compounding restrictions on six peptides. The announcement follows the FDA advisory committee vote in July and the “interim access” policy we covered when it went to the White House for review (earlier article). HHS has now published the policy document itself, so this article sticks to what that document says, with news coverage used only for context.

What was announced

The document is titled as an interim enforcement policy for certain 503A peptides. It is enforcement discretion, not a change to the law and not a final rule: HHS says it “does not intend to take enforcement action” against covered compounders while the 503A bulks list for peptides is developed through rulemaking. News reports quote HHS as saying the policy “does not grant FDA approval or establish clinical safety and effectiveness.”

The six peptides named in Appendix A are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The covered compounders are state-licensed pharmacies, federal facilities and licensed physicians. HHS frames the policy as a “more controlled alternative” to unregulated sellers.

The conditions

Enforcement discretion applies only if every condition is met. In summary, the document requires that:

• the peptide is one of the six, matches the identity (sequence, structure, molecular weight, formula) and the routes listed in Appendix B for that peptide;
• the bulk substance comes from an FDA-registered facility and is covered by a valid certificate of analysis whose results meet the document’s testing standard;
• the original manufacturer, not a repacker, relabeler or distributor, is FDA-registered and CGMP-compliant, and its physical location appears on the COA;
• compounders report the products compounded, serious adverse events and quality problems to FDA (MedWatch) and the relevant states;
• the label states: “This is a compounded drug product. Not for resale.”;
• each product contains one of the six ingredients only, and the only device included is an FDA 510(k)-cleared syringe;
• the usual 503A rules still apply, including a patient-specific prescription and no insanitary conditions.

The testing standard

The document includes a table of tests the COA must cover. It lists identity, assay, purity and impurities, peptide content, nitrosamines, residual solvents, elemental impurities, residual TFA and fluoride, counter-ion content, water content, bioburden and bacterial endotoxins. A footnote calls endotoxin and microbial criteria critical quality attributes for injectables. Many of these go beyond the purity-and-identity report most research-material COAs contain; our explainers on purity versus content, TFA versus acetate and sterility versus endotoxin testing cover what several of these items mean.

Routes and forms

Appendix B ties each peptide to specific forms and routes. The document lists, for example, BPC-157 (acetate) for several routes including oral and topical; KPV (acetate) topical and oral; semax (free base) intranasal; and TB-500, epitalon and MOTS-c as injectables. For oral products, compounders must keep documentation that the formulation reaches adequate oral bioavailability in humans, a point the document describes as “inherently difficult and complex.”

How long it lasts

No effective date or end date is stated. The policy applies “until a peptide bulk drug substance is addressed in a final rule,” and HHS says it may revisit the policy in whole or in part, including if a safety signal or product-quality issue arises. Pharmacy groups report they are still waiting on rulemaking.

What the document says about the evidence

Appendix B gives HHS’s justification for each peptide and notes that several had been in FDA’s “Category 2” (substances with safety concerns) until April 22, 2026. It also states that FDA’s drug-center staff recommended against listing them, while the advisory committee voted in favor for most. The document itself describes several of its justifications as resting on limited evidence, such as mechanistic rather than observed safety concerns, or studies of related molecules or in rodents. News coverage adds that there are no published clinical trials showing that these specific peptides work in humans for any condition.

What it says, and does not say, about research-use-only material

The document does not directly address research-use-only products or non-prescription sales. It does state that the policy is meant to discourage the “continued, widespread use” of research-use-only peptides from foreign manufacturers. The conditions apply to prescription compounding by licensed parties; they do not authorize any other kind of sale, and the document does not say how enforcement will treat sellers outside the policy. Readers should not infer permission from this policy for anything it does not name.

Open questions

• When does the policy take effect, and how long is “temporary”?
• How will the manufacturer-registration and COA conditions work in practice, given that few registered manufacturers currently supply these peptides?
• How will FDA respond to the citizen petition asking it to block compounding of these peptides?
• What will the final rule say, and will the advisory committee’s further review of other peptides change the list?

Sources

1. HHS, interim enforcement policy for certain 503A peptides, Appendix A and B (hhs.gov, PDF published October 28, 2026).
2. ABC News, “Some wellness peptides will become widely available, HHS says,” October 28, 2026.
3. National Community Pharmacists Association, “FDA grants enforcement discretion to compounding six peptides,” October 29, 2026.
4. Endpoints News, “Citing ‘safety’ and ‘freedom,’ HHS will allow compounding of certain wellness peptides,” October 28, 2026 (headline and summary only; paywalled).

Not every outlet’s full text could be read; where a detail rests on a single source it is attributed to that source above.

Related reading

• HHS Peptide Interim Access Policy: What We Know
• Peptide Compounding Policy: Citizen Petition and HHS Update
• What “Research Use Only” Means on Peptides
• How to Read a Peptide COA

← Back to all articles